Elsevier / MEDai Appoints Tom Zajac as New President
Orlando, FL, November 28, 2011 – Elsevier/MEDai, the leader in predictive clinical analytic solutions, today announced that Thomas H. Zajac has been named the company’s new President. Elsevier / MEDai provides solutions for providers, health plans and healthcare organizations focused on population management, physician profiling, regulatory compliance and clinical surveillance to improve healthcare outcomes.
Elsevier / MEDai began with one simple idea: to help healthcare organizations transform volumes of clinical data into actionable insight, enabling better decisions and improving the quality, cost and effectiveness of the care process. Tom brings over 25 years experience in building clinical, financial, and operational performance improvement solutions for both vendor and healthcare organizations that provides a tremendous opportunity to energize the growth and vision of Elsevier / MEDai.
“Tom’s appointment comes at an important time as payers and providers are looking more to analytics to pull insights out of data to drive population management and physician performance programs”, said Michael Hansen, CEO of Elsevier Health Sciences. “Under his leadership MEDai will continue to help empower customers to make sound clinical and financial decisions that reduce risk, lower costs and improve the quality of care.”
Tom was formerly President of CareScience, spending eight years building the company into one of the leading providers of integrated quality improvement, regulatory reporting, outcomes research, HIE data exchange, and transformational services to over 250 health organizations. Prior to CareScience, Tom spent eleven years building Transition Systems’ (TSI) success as the leader in healthcare decision support, with 1200 US and international provider and payer customers. TSI was acquired by Eclipsys, where Tom established and became President of the Business Solutions Division, providing advisory and transformation consulting to customers across its spectrum of products.
“MEDai is in a unique position to impact the healthcare process, with our award winning clinical analytics, process knowledge, and clinical insight,” said Tom. “Our role as a true partner is to provide our customers with product and service solutions that both support their current needs and expands to support the industry’s evolution to true population health and longitudinal care.”
Tom is a Senior Scholar with the Jefferson University School of Public Health, is a prior contributor to the Center for Healthcare Transformation, and has presented at both national and international forums on healthcare management. Most recently, Tom was Managing Director of Zajac and Associates, LLC, providing product and strategy services to private equity, vendor and provider customers in healthcare.
# # #
About Elsevier / MEDai
Elsevier/MEDai, Inc. is a leading health information company offering award-winning solutions for the improvement of healthcare delivery. Utilizing cutting-edge technology, payers and care management organizations are able to predict patients at risk, identify cost drivers for their high-risk population, forecast future health plan costs, evaluate patient patterns over time, and improve outcomes. For more information on Elsevier / MEDai, visit www.medai.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Vice President Global Corporate Relations, Elsevier
+1 215 239 3508